Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients

Abstract

Thalidomide has been reported as efficacious in refractory cutaneous lupus erythematosus (LE). The most fearful side-effects are teratogenicity and neuropathy. We reported clinical efficacy of long-term low-dose use of thalidomide in 65 patients with LE, emphasizing the prevalence of adverse effects, especially of neuropathy and its related factors. Data obtained from medical records included age, sex, disease duration, and the presence of diagnostic criteria for systemic lupus erythematosus (SLE), the extent and activity of cutaneous lesions and previous treatments. Sixty-three patients (98.9%) presented complete or partial improvement with thalidomide therapy. Drowsiness occurred in 50 patients (77%). Twenty-eight patients (43.2%) presented neuropathy symptoms. Nerve conduction studies were done in 21 (75%) of them and were abnormal in 12 (57%). With the interruption of thalidomide, 24 (82.5%) had complete or partial improvement of neuropathy symptoms and 23 (82%) of them had cutaneous relapse. There were no significant differences between those who developed or not neuropathy in treatment duration, age, total dose and systemic versus cutaneous LE. In conclusion, thalidomide can be used in refractory cutaneous LE with great efficacy and relative security. Controlled studies with schemes with lower doses or intermittent usage or alternative drugs are wanted to reduce the burden of cutaneous morbidity of lupus erythematosus.

Keywords

discoid lupus lupus erythematosus refractory subacute lupus thalidomide treatment

Get full access to this article

View all access options for this article.

References

Soares M , Reis L , Papi JAS , Cardoso CRL. Rate, pattern and factors related to damage in Brazilian systemic lupus erythematosus patients . Lupus 2003; 12: 788-794 .

Knop J , Bonsmann G , Happle R et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus . Br J Dermatol 1983; 108: 461-466 .

Stevens RJ , Andujar C , Edwards CJ et al. Thalidomide in the treatment of cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients . Br J Rheumatol 1997; 36: 353-359 .

Housman TS , Jorizzo JL , McCarty MA , Grummer SE , Fleischer AB , Sutej PG. Low-dose thalidomide therapy for cutaneous lesions of lupus erythematosus . Arch Dermatol 2003; 139: 50-54 .

Kyriakis KP , Kontochristopoulos GJ , Panteleos DN. Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus . Int J Dermatol 2000; 39: 218-222 .

Walchner M , Meurer M , Plewing G , Messer G. Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus . Int J Dermatol 2000; 39: 383-388 .

Calabrese L , Fleischer AB. Thalidomide: current and potential clinical applications . Am J Med 2000; 108: 487-495 .

Sato EI , Assis LSS , Lorenzi VP , Andrade LEC. Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus . Rev Assoc Med Bras 1998; 44: 289-293 .

Ordi-Ros J , Cucurull E , Mauri M , Bujan S , Vilardell M. Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy . J Rheumatol 2000; 27: 1429-1433 .

10.

Powell RJ , Gardner-Medwin JNM. Guideline for the clinical use and dispensing of thalidomide . Postgrad Med J 1994; 70: 901-904 .

11.

Tan EM , Cohen AS , Fries JF et al. The revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1982; 25: 1271-1277 .

12.

Sheskin J , Yaar I. Motor-conduction velocity of cubital nerves in patients with leprosy reactions. Summary of a 13-year observation series during thalidomide therapy . Hautarzt 1979; 30: 376-379 .

13.

Wulff CH , Hoyer H , Asboe-Hansen G , Brodthaden H. Development of polyneuropathy during thalidomide therapy . Br J Dermatol 1985; 112: 475-480 .

14.

Ochonisky S , Verroust J , Bastuji-Garin S , Gherardi R , Revuz J. Thalidomide neuropathy incidence and clinicoelectrophysiologic findings in 42 patients . Arch Dermatol 1994; 130: 66-69 .

15.

Gardner-Medwin JMM , Smith NJ , Powell RJ. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet’s disease: use of neurophysiological studies to detect thalidomide neuropathy . Ann Rheum Dis 1994; 53: 828-832 .

16.

Hafström T. Polyneuropathy after Neurosedyn (Thalidomide) and its prognosis . Acta Neurol Scand 1967; 43(Suppl. 32): 1-41 .

17.

Krucke W , Von Hartrott HH , Schöder JM , Thomas E , Gibbels E , Scheid W. Fortschr Neurol Psychiatr Grenzgeb.1971; 39: 15-50 .

18.

Chaudhry V , Cornblath DR , Mellitis ED et al. Inter-and intra-examiner reliability of nerve conduction measurements in normal subjects . Ann Neurol 1991; 30: 841-843 .

19.

Bleasel AF , Tuck RR. Variability of repeated nerve conduction studies . Electroencephlogr Clin Neurophysiol 1991; 81: 417-420 .